Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses

Abstract While vaccines remain the best tool for preventing influenza virus infections, they have demonstrated low to moderate effectiveness in recent years. Seasonal influenza vaccines typically consist of wild-type influenza A and B viruses that are limited in their ability to elicit protective im...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	James D. Allen, Ted M. Ross
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cac564263c8947b381a15ab023f491cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cac564263c8947b381a15ab023f491cd
record_format	dspace
spelling	oai:doaj.org-article:cac564263c8947b381a15ab023f491cd2021-12-02T11:37:19ZNext generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses10.1038/s41598-020-79590-72045-2322https://doaj.org/article/cac564263c8947b381a15ab023f491cd2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79590-7https://doaj.org/toc/2045-2322Abstract While vaccines remain the best tool for preventing influenza virus infections, they have demonstrated low to moderate effectiveness in recent years. Seasonal influenza vaccines typically consist of wild-type influenza A and B viruses that are limited in their ability to elicit protective immune responses against co-circulating influenza virus variant strains. Improved influenza virus vaccines need to elicit protective immune responses against multiple influenza virus drift variants within each season. Broadly reactive vaccine candidates potentially provide a solution to this problem, but their efficacy may begin to wane as influenza viruses naturally mutate through processes that mediates drift. Thus, it is necessary to develop a method that commercial vaccine manufacturers can use to update broadly reactive vaccine antigens to better protect against future and currently circulating viral variants. Building upon the COBRA technology, nine next-generation H3N2 influenza hemagglutinin (HA) vaccines were designed using a next generation algorithm and design methodology. These next-generation broadly reactive COBRA H3 HA vaccines were superior to wild-type HA vaccines at eliciting antibodies with high HAI activity against a panel of historical and co-circulating H3N2 influenza viruses isolated over the last 15 years, as well as the ability to neutralize future emerging H3N2 isolates.James D. AllenTed M. RossNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q James D. Allen Ted M. Ross Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses
description	Abstract While vaccines remain the best tool for preventing influenza virus infections, they have demonstrated low to moderate effectiveness in recent years. Seasonal influenza vaccines typically consist of wild-type influenza A and B viruses that are limited in their ability to elicit protective immune responses against co-circulating influenza virus variant strains. Improved influenza virus vaccines need to elicit protective immune responses against multiple influenza virus drift variants within each season. Broadly reactive vaccine candidates potentially provide a solution to this problem, but their efficacy may begin to wane as influenza viruses naturally mutate through processes that mediates drift. Thus, it is necessary to develop a method that commercial vaccine manufacturers can use to update broadly reactive vaccine antigens to better protect against future and currently circulating viral variants. Building upon the COBRA technology, nine next-generation H3N2 influenza hemagglutinin (HA) vaccines were designed using a next generation algorithm and design methodology. These next-generation broadly reactive COBRA H3 HA vaccines were superior to wild-type HA vaccines at eliciting antibodies with high HAI activity against a panel of historical and co-circulating H3N2 influenza viruses isolated over the last 15 years, as well as the ability to neutralize future emerging H3N2 isolates.
format	article
author	James D. Allen Ted M. Ross
author_facet	James D. Allen Ted M. Ross
author_sort	James D. Allen
title	Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses
title_short	Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses
title_full	Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses
title_fullStr	Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses
title_full_unstemmed	Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses
title_sort	next generation methodology for updating ha vaccines against emerging human seasonal influenza a(h3n2) viruses
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cac564263c8947b381a15ab023f491cd
work_keys_str_mv	AT jamesdallen nextgenerationmethodologyforupdatinghavaccinesagainstemerginghumanseasonalinfluenzaah3n2viruses AT tedmross nextgenerationmethodologyforupdatinghavaccinesagainstemerginghumanseasonalinfluenzaah3n2viruses
_version_	1718395787495342080

Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses

Ejemplares similares